HANXBIO-B repurchases 27,800 H shares for HKD 0.84 million; outstanding float trimmed by 0.02%

Bulletin Express05-14

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, HKEX: 03378) disclosed a Next Day Disclosure Return showing a fresh share buy-back executed on 14 May 2026.

The company repurchased 27,800 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.46 to HKD 32.00, with a volume-weighted average cost of HKD 30.16 per share. Total cash outlay reached approximately HKD 0.84 million. All repurchased shares have been retained as treasury stock.

Following the transaction, the number of issued shares (excluding treasury shares) fell from 135.62 million to 135.59 million, a marginal decline of 0.02%. Treasury shares increased to 0.63 million, while the total issued share count remained unchanged at 136.22 million.

Under the repurchase mandate approved on 12 February 2026, HANXBIO-B is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 626,400 shares, representing 0.46% of the issued share capital on the mandate date.

In accordance with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 13 June 2026. The board confirmed that all repurchases were executed in compliance with relevant regulations and that requisite procedural and filing requirements have been met.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107048235?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107048235","market":"hk","top_or_hot":-1,"title":"HANXBIO-B repurchases 27,800 H shares for HKD 0.84 million; outstanding float trimmed by 0.02%","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, HKEX: 03378) disclosed a Next Day Disclosure Return showing a fresh share buy-back executed on 14 May 2026.</p>\n<p>The company repurchased 27,800 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.46 to HKD 32.00, with a volume-weighted average cost of HKD 30.16 per share. Total cash outlay reached approximately HKD 0.84 million. All repurchased shares have been retained as treasury stock.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) fell from 135.62 million to 135.59 million, a marginal decline of 0.02%. Treasury shares increased to 0.63 million, while the total issued share count remained unchanged at 136.22 million.</p>\n<p>Under the repurchase mandate approved on 12 February 2026, HANXBIO-B is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 626,400 shares, representing 0.46% of the issued share capital on the mandate date.</p>\n<p>In accordance with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 13 June 2026. The board confirmed that all repurchases were executed in compliance with relevant regulations and that requisite procedural and filing requirements have been met.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B repurchases 27,800 H shares for HKD 0.84 million; outstanding float trimmed by 0.02%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B repurchases 27,800 H shares for HKD 0.84 million; outstanding float trimmed by 0.02%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-14 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, HKEX: 03378) disclosed a Next Day Disclosure Return showing a fresh share buy-back executed on 14 May 2026.</p>\n<p>The company repurchased 27,800 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.46 to HKD 32.00, with a volume-weighted average cost of HKD 30.16 per share. Total cash outlay reached approximately HKD 0.84 million. All repurchased shares have been retained as treasury stock.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) fell from 135.62 million to 135.59 million, a marginal decline of 0.02%. Treasury shares increased to 0.63 million, while the total issued share count remained unchanged at 136.22 million.</p>\n<p>Under the repurchase mandate approved on 12 February 2026, HANXBIO-B is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 626,400 shares, representing 0.46% of the issued share capital on the mandate date.</p>\n<p>In accordance with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 13 June 2026. The board confirmed that all repurchases were executed in compliance with relevant regulations and that requisite procedural and filing requirements have been met.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1107048235","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107048235","pubTimestamp":1778762573,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, HKEX: 03378) disclosed a Next Day Disclosure Return showing a fresh share buy-back executed on 14 May 2026. The company repurchased 27,800 H...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"HANXBIO-B以84万港元回购2.78万股H股；流通股减少0.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B, HKEX: 03378) disclosed a Next Day Disclosure Return showing a fresh share buy-back executed on 14 May 2026.\nThe company repurchased 27,800 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 29.46 to HKD 32.00, with a volume-weighted average cost of HKD 30.16 per share. Total cash outlay reached approximately HKD 0.84 million. All repurchased shares have been retained as treasury stock.\nFollowing the transaction, the number of issued shares (excluding treasury shares) fell from 135.62 million to 135.59 million, a marginal decline of 0.02%. Treasury shares increased to 0.63 million, while the total issued share count remained unchanged at 136.22 million.\nUnder the repurchase mandate approved on 12 February 2026, HANXBIO-B is authorised to buy back up to 13.62 million shares. Cumulative repurchases now stand at 626,400 shares, representing 0.46% of the issued share capital on the mandate date.\nIn accordance with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 13 June 2026. The board confirmed that all repurchases were executed in compliance with relevant regulations and that requisite procedural and filing requirements have been met.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107048235","isCrawlerRequest":true}